Want to see ALLO full AI Analyst Report?
Top Page
Allogene Therapeutics
(NASDAQ:ALLO)
Select Model
Select Model
Rating:51Neutral
Price Target:
$2.00
▼(-7.83% Downside)
Action:Reiterated
Date:08/18/26
The score is primarily held back by very weak financial performance (large losses and ongoing negative free cash flow), only partly offset by a manageable balance sheet and improving burn trends. Technicals are neutral-to-mildly positive, while valuation is constrained by negative earnings and no dividend. The latest earnings call added meaningful support due to clear milestones, regulatory validation, and encouraging early signals, but clinical, safety, and statistical readout risks remain.
Positive Factors
Regulatory validation of Cema-Cel
RMAT and Fast Track designations validate Cema-Cel’s relevance to an unmet need and may support more efficient regulatory interaction, potentially improving the program’s path toward approval if clinical efficacy and safety are confirmed.
Negative Factors
Minimal revenue and substantial operating losses
Allogene remains a development-stage biotech without meaningful recurring product revenue, while large losses reflect substantial research and development spending. Until a candidate is approved and commercialized, earnings quality and revenue scalability remain unproven.
Read all positive and negative factors
Positive Factors
Negative Factors
Regulatory validation of Cema-Cel
RMAT and Fast Track designations validate Cema-Cel’s relevance to an unmet need and may support more efficient regulatory interaction, potentially improving the program’s path toward approval if clinical efficacy and safety are confirmed.
Read all positive factors
Allogene Therapeutics (ALLO) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$749.72M
Dividend YieldN/A
Average Volume (3M)8.88M
Price to Earnings (P/E)―
Beta (1Y)1.69
Revenue GrowthN/A
EPS Growth40.16%
CountryUS
Employees151
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.67
Shares Outstanding345,490,880
10 Day Avg. Volume5,424,436
30 Day Avg. Volume8,884,984
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)1.03
Price to Sales (P/S)0.00
P/FCF Ratio-2.02
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$10.25Price Target Upside372.35% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-0.6
Revenue Forecast (FY)$2.98M
Allogene Therapeutics Business Overview & Revenue Model
Company Description
Allogene Therapeutics, Inc. operates as a clinical-stage immuno-oncology firm dedicated to the creation and commercialization of genetically engineered allogeneic T-cell therapies for the treatment of various cancers. A pivotal product in their de...
How the Company Makes Money
Allogene Therapeutics does not have recurring product revenue from marketed therapies; its primary revenue, when reported, has historically come from collaboration-related arrangements rather than commercial sales. The company’s monetization model...
Allogene Therapeutics Earnings Call Summary
Earnings Call Date:Aug 12, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Oct 29, 2026
Earnings Call Sentiment Positive
The call emphasized significant operational and clinical progress: regulatory validation (RMAT/Fast Track), strong MRD clearance signals for ALPHA3 with favorable outpatient/community deliverability, accelerated site activation, meaningful ALLO-316 responses in a difficult solid tumor setting, and rapid enrollment momentum for ALLO-329. These positives are tempered by safety challenges in ALLO-316, small sample sizes for some encouraging signals, and uncertainty around the likelihood of achieving statistical significance at the interim EFS analysis. Near-term milestones are clearly defined (Q4 RESOLUTION update, 2027 ALPHA3 updates), but key outcome readouts and broader competitive dynamics remain potential risks.Positive Updates
Regulatory Designations for ALPHA3 (Cema-Cel)
FDA granted RMAT and Fast Track designations for Cema-Cel in first-line consolidation, recognizing MRD positivity after first-line treatment as an unmet need and acknowledging Cema-Cel's potential to meet that need.
Negative Updates
Safety Challenges with ALLO-316
The ALLO-316 program faced real safety challenges that nearly prompted conventional stopping decisions; although a management algorithm was developed, toxicity remains a notable risk and the dataset is small.
Read all updates
Q2-2026 Updates
Positive
Negative
Regulatory Designations for ALPHA3 (Cema-Cel)
FDA granted RMAT and Fast Track designations for Cema-Cel in first-line consolidation, recognizing MRD positivity after first-line treatment as an unmet need and acknowledging Cema-Cel's potential to meet that need.
Read all positive updates
Company Guidance
Management reiterated clear timelines and numeric goals: ALPHA3 is targeting randomization of 220 patients with the interim EFS analysis expected roughly mid‑2027 (timing unchanged), the company met its >80‑site activation goal in July and now expects ~100 sites active by year‑end (majority U.S., plus Canada, Australia, South Korea); the April interim/futility read showed rapid MRD clearance in a majority of patients, most treated entirely outpatient with no treatment‑related hospitalizations and roughly one‑third of patients from community sites. The FDA granted RMAT and Fast Track for Cema‑Cel; ALLO‑329 (RESOLUTION) will report clinical and translational data in Q4 (dose cohorts of 20M, 40M and 80M cells, additional doses contemplated, and nine patients previously treated across LD and non‑LD arms); ALLO‑316 (TRAVERSE) produced a 31% confirmed ORR in CD70‑high RCC with five confirmed responders (none progressed with 8 to >18+ months follow‑up). Management said investors should expect ALLO‑329 updates by year‑end and ongoing ALPHA3 enrollment and potential data updates through 2027 while pursuing efficient regulatory engagement.Allogene Therapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
28
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.64M | 0.00 | 22.00K | 95.00K | 156.00K | 114.09M |
| Gross Profit | -32.45M | -12.36M | 22.00K | 95.00K | -14.14M | 114.09M |
| EBITDA | -152.53M | -177.45M | -243.33M | -313.07M | -326.12M | -171.60M |
| Net Income | -165.49M | -190.89M | -257.59M | -327.26M | -340.41M | -182.05M |
Balance Sheet | ||||||
| Total Assets | 550.09M | 415.90M | 548.71M | 642.84M | 821.58M | 1.05B |
| Cash, Cash Equivalents and Short-Term Investments | 332.60M | 250.21M | 292.48M | 448.70M | 517.32M | 457.30M |
| Total Debt | 70.35M | 83.25M | 90.76M | 95.12M | 101.12M | 73.13M |
| Total Liabilities | 113.92M | 123.36M | 126.53M | 130.60M | 154.70M | 125.63M |
| Stockholders Equity | 436.18M | 292.54M | 422.18M | 512.23M | 666.88M | 925.20M |
Cash Flow | ||||||
| Free Cash Flow | -102.60M | -149.63M | -200.99M | -239.25M | -225.71M | -206.26M |
| Operating Cash Flow | -102.20M | -149.25M | -200.30M | -237.73M | -220.52M | -184.81M |
| Investing Cash Flow | -131.60M | 95.56M | 75.69M | 163.29M | 106.16M | 163.66M |
| Financing Cash Flow | 220.09M | 30.16M | 116.67M | 95.69M | 2.95M | 11.96M |
Allogene Therapeutics Technical Analysis
Positive
2.17
Price Trends
1.98
Positive
2.10
Positive
1.93
Positive
Market Momentum
0.05
Negative
57.93
Neutral
56.99
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ALLO, the sentiment is Positive. The current price of 2.17 is above the 20-day moving average (MA) of 2.02, above the 50-day MA of 1.98, and above the 200-day MA of 1.93, indicating a bullish trend. The MACD of 0.05 indicates Negative momentum. The RSI at 57.93 is Neutral, neither overbought nor oversold. The STOCH value of 56.99 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ALLO.
Allogene Therapeutics Risk Analysis
Allogene Therapeutics disclosed 78 risk factors in its most recent earnings report. Allogene Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Allogene Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $749.72M | -3.04 | -50.04% | ― | ― | 40.16% | |
48 Neutral | $355.11M | -5.29 | -41.69% | ― | 6280.00% | -212.54% | |
48 Neutral | $406.79M | -6.76 | 72.64% | ― | 51.98% | 17.68% | |
46 Neutral | $157.27M | -1.31 | -108.05% | ― | ― | 45.08% | |
44 Neutral | $281.84M | -1.27 | -242.28% | ― | ― | 21.31% |
* Healthcare Sector Average
ALLO
Allogene Therapeutics
2.04
0.88
75.86%
ABEO
Abeona Therapeutics
6.01
-0.89
-12.90%
FHTX
Foghorn Therapeutics
6.69
1.28
23.66%
TNYA
Tenaya Therapeutics
0.70
-0.40
-36.73%
NMRA
Neumora Therapeutics, Inc.
1.56
-0.20
-11.36%
Allogene Therapeutics Corporate Events
Business Operations and StrategyExecutive/Board ChangesPrivate Placements and FinancingRegulatory Filings and ComplianceShareholder Meetings
Allogene Launches ATM Offering to Bolster Capital Flexibility
Positive
Jun 22, 2026
At its June 18, 2026 annual meeting, Allogene Therapeutics’ stockholders elected three Class II directors to serve until the 2029 meeting, approved executive compensation on an advisory basis, and opted for annual say-on-pay votes, which the...
Executive/Board Changes
Allogene Therapeutics Names Zachary Roberts as New CEO
Positive
May 28, 2026
On May 28, 2026, Allogene Therapeutics’ board appointed Zachary Roberts, M.D., Ph.D., as president and chief executive officer, effective July 1, 2026, succeeding co-founder David Chang, M.D., Ph.D., whose last day in those roles will be Jun...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.